New horizons in anticoagulationdirect oral anticoagulants and their implications in oral surgery

  1. Víctor Serrano Sánchez 1
  2. Jorge Ripollés de Ramón 2
  3. L. Collado Yurrita 3
  4. Iris Vaello Checa 1
  5. Constantino Colmenero Ruiz 4
  6. Alexandra Helm 5
  7. María José Ciudad Cabañas 6
  8. Victoriano Serrano Cuenca 7
  1. 1 DDS. Collaborator in the Department of Medicine at the Faculty of Medicine. Faculty of Dentistry of Complutense University of Madrid
  2. 2 DDS, PhD. Collaborator in Departament of Oral Medicine & Orofacial Surgery. Faculty of Dentistry of Complutense University of Madrid. Collaborate Professor at the Master of Oral Surgery and Implantology UC
  3. 3 Director of the Department of Medicine. Faculty of Medicine of Complutense University of Madrid
  4. 4 DDS. Faculty of Dentistry of Complutense University of Madrid. Collaborator in the Master in Oral Surgery at the University Hospital of Príncipe de Asturias (UAH)
  5. 5 DDS. Faculty of Dentistry of Complutense University of Madrid
  6. 6 Department of Medicine. Faculty of Medicine of Complutense University of Madrid
  7. 7 MD, DDS, PHD. Professor of Departament of Oral Medicine & Orofacial Surgery. Faculty of Dentistry of Complutense University of Madrid
Mostrar afiliaciones +
Revista:
Medicina oral, patología oral y cirugía bucal. Ed. inglesa

ISSN: 1698-6946

Año de publicación: 2017

Volumen: 22

Número: 5

Páginas: 12

Tipo: Artículo

DOI: 10.4317/MEDORAL.21862 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Medicina oral, patología oral y cirugía bucal. Ed. inglesa

Objetivos de desarrollo sostenible

Resumen

Thrombotic disorders remain a leading cause of death in the Western World. For decades, vitamin K antagonists used in the prevention of this pathology, such as warfarin or sintrom, were the only oral agents available for long-term anticoagulation, in spite of their disadvantages. An electronic database search was carried out on MedLine and The Cochrane Library Plus, without restrictions on the type of study nor dates, in English and Spanish. Abstracts were reviewed, and complete articles if necessary, considering all articles that included recommendations on DOACs and oral surgery. In recent years, the so-called “new oral anticoagulants” have been introduced in clinical practice to treat those patients whose medical conditions require long-term anticoagulant treatment, replacing traditional oral anticoagulants. The new oral anticoagulants represent new therapeutic options, with a number of advantages such as poor interaction with food, minor drug interactions, and do not require periodic dose adjustments or routine controls. The purpose of this review is to establish an update on the new oral anticoagulants: Dabigatran, Rivarozaban, Apixaban and Edoxaban.

Referencias bibliográficas

  • Go, AS, Hylek, EM, Phillips, KA, Chang, Y, Henault, LE, Selby, JV. (2001). Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 285. 2370
  • Krijthe, BP, Kunst, A, Benjamin, EJ, Lip, GYH, Franco, OH, Hofman, A. (2013). Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 34. 2746
  • Wynn, GJ, Todd, DM, Webber, M, Bonnett, L, McShane, J, Kirchhof, P. (2014). The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace. The Oxford University Press. 167. 965
  • Imberti, D, Gallerani, M, Manfredini, R. (2012). Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. J Thromb Thrombolys. 34. 208
  • Firriolo, FJ, Hupp, WS. (2012). Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 113. 431
  • Levy, JH, Key, NS, Azran, MS. (2010). Novel oral anticoagulants: implications in the perioperative setting. Anesthesiology. 113. 726
  • Ezekowitz, MD, Connolly, S, Parekh, A, Reilly, PA, Varrone, J, Wang, S. (2009). Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 157. 805
  • Conolly, SJ, Ezekowitz, MD, Yusuf, S, Eikelboom, J, Oldgren, J, Parekh, A. (2009). Dabiagtran versus Warfarin in patients with Atrial Fibrillation. N Engl J Med. 361. 1139
  • ROCKET AF Study, Investigators. (2010). Rivaroxaban — once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 159.
  • Patel, MR, Mahaffey, KW, Garg, J, Pan, G, Singer, DE, Hacke, W. (2011). Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 365. 883
  • Connolly, SJ, Eikelboom, J, Joyner, C, Diener, HC, Hart, R, Golitsyn, S. (2011). Apixaban in patients with atrial fibril- lation. N Engl J Med. 364. 806
  • Lopes, RD, Alexander, JH, Al-Khatib, SM, Ansell, J, Diaz, R, Easton, JD. (2010). Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 159. 331
  • Granger, CB, Alexander, JH, McMurray, JJV, Lopes, RD, Hylek, EM, Hanna, M. (2011). Apixaban versus Warfarin in patients with Atrial Fibrillation. N Eng J Med. 365. 981
  • Matsushima, N, Lee, F, Sato, T, Weiss, D, Mendell, J. (2013). Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharm Drug Dev. 2. 358
  • Ruff, CT, Giugliano, RP, Antman, EM, Crugnale, Se, Bocanegra, T, Mercuri, M. (2010). Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 160. 635
  • Giugliano, RP, Ruff, CT, Braunwald, E, Murphy, SA, Wiviott, SD, Halperin, JL. (2013). Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Eng J Med. 269. 2093
  • Arcelus, JI, Cairols, M, Granero, X, Jiménez, D, Llau, JV, Monreal, M. (2009). Nuevos anticoagulantes orales: una visión multidisciplinaria. Med Clin (Barc). 133. 508
  • Heidbuchel, H, Verhamme, P, Alings, M, Antz, M, Hacke, W, Oldgren, J. (2013). European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants inpatients with non-valvular atrial fibrillation. Europace. 15. 625
  • Weitz, JI, Pollack, CV Jr. (2015). Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 114. 1113
  • Wysokinski, WE, McBaneR, D. (2012). Periprocedural bridging management of anticoagulation. Circulation. 126. 486
  • Du, S, Weiss, C, Christina, G, Krämer, S, Wehling, M, Krämer, R. (2015). Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods. Clin Chem Lab Med. 53. 1237
  • Harenberg, J, Du, S, Wehling, M, Zolfaghari, S, Weiss, C, Krämer, R. (2016). Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study. Clin Chem Lab Med. 54. 275
  • Barrios, V, Calderón, A, Escobar, C, De la Figuera, M. (2012). Pacientes con fibrilación auricular asistidos en consultas de atención primaria. Estudio Val-FAAP. Rev Esp Cardiol. 65. 47-53
  • Chao, T, Lin, YJ, Tsao, HM, Tsai, CF, Lin, WS, Chang, SL. (2011). CHADS2 and CHA2DS2-VASc Scores in the Prediction of Clinical Outcomes in Patients With Atrial Fibrillation After Catheter Ablation. J Am Coll Cardiol. 58. 2380
  • Pisters, R, Lane, DA, Nieuwlaat, R, De Vos, RNC, Crijns, HJG, Lip, GYH. (2010). A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. Chest. 138. 1093
  • Ment, J. (2015). Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial brillation. Vasc Health Risk Manag. 11. 317
  • Ebright, J, Mousa, SA. (2015). Oral anticoagulants and status of antidotes for the reversal of bleeding risk. Clin Appl Thromb Hemost. 21. 105
  • Liotta, EM, Levasseur-Franklin, KE, Naidech, AM. (2015). Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban. Curr Opin Crit Care. 21. 127
  • Constantinides, F, Rizzo, R, Pascazio, L, Maglione, M. (2016). Managing patients taking novel oral anticoagulants (NOAs) in dentistry: a discussion paper on clinical implications. Oral Health. 16. 5
  • Elad, S, Marshall, J, Meyerowitz, C, Connolly, G. (2016). Novel anticoagulants: general overview and practical considerations for dental practitioners. Oral Diseases. 22. 23-32
  • González Fernández-Tresguerres, F, Álvarez Sirvent, A, Torres García-Denche, J, Fernández-Tresguerres Hernández-Gil, I. (2016). Nuevos anticoagulantes orales: repercusión odontológica. Cient Dent. 2. 139
  • Mauprivez, C, Khonsari, R, Razouk, O, Goudot, P, Lesclous, P, Descroix, V. (2016). Management of dental extraction in patients undergoing anticoagulant oral direct treatment. A pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol. 122. 146-155
  • Hong, CH, Islam, I. (2013). AntiThrombotic Therapy: Implications for Invasive Outpatient Procedures in Dentistry. J Blood Disorders Transf. 4. 166
  • Wang, X, Mondal, S, Wang, J, Tirucherai, G, Zhang, D, Boyd, RA. (2014). Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs. 14. 147
  • Crowther, M, Crowther, MA. (2015). Antidotes for novel oral anticoagulants: current status and future potential. Arterioscler Thromb Vasc Biol. 35. 1736
  • Weitz, JI, Pollack, CV Jr. (2015). Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 114. 1113
  • Pabinger, I, Brenner, B, Kalina, U, Knaub, S, Nagy, A, Ostermann, H. (2008). Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 6. 622
  • Hu, TY, Vaidya, VR, Asirvatham, SJ. (2016). Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 12. 35-44
Fuente de los datos: Dialnet